Skip to main content

Table 2 Performance status and baseline PSA level as well as PSA changes 8 weeks after therapy

From: Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study

Number ECOG1 ECOG2 Baseline PSA (ng/ml) PSA2 (ng/ml) PSA change (%)
1 1 1 226 529 134.7
2 1 1 334 243 −27.2
3 2 2 376 141 −62.5
4 1 1 853 590a −30.8
5 1 1 148 46 −68.9
6 0 0 20 5 −75.0
7 1 1 263 355 35.0
8 1 1 790 293 −62.9
9 1 1 379 58 −84.7
10 3 2 5 21 320.0
  1. ECOG1 baseline Eastern Cooperative Oncology Group performance status, ECOG2 Eastern Cooperative Oncology Group performance status 2 months after therapy, PSA prostatic specific antigen, PSA2 prostatic specific antigen 2 months after therapy
  2. a4 weeks after Tx, PSA decreased to 71 ng/ml